Fulcrum Therapeutics Approves Restructuring Plan To Reduce Operating Expenses And Preserve Capital; To Reduce Full-Time Workforce By 85% From 57 To 9

Fulcrum Therapeutics

Fulcrum Therapeutics

FULC

0.00

Fulcrum expects to incur aggregate charges of approximately $4.2 million in connection with the restructuring plan, consisting primarily of employee severance, employee benefits and related costs. Fulcrum communicated the workforce reduction on June 4, 2026, and expects that substantially all of these charges will result in future cash expenditures and will be incurred during the second quarter of 2026.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.